Shanxi C&Y Pharmaceutical Group Co Ltd - Asset Resilience Ratio

Latest as of September 2020: 0.26%

Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has an Asset Resilience Ratio of 0.26% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥5.00 Million
≈ $731.66K USD Cash + Short-term Investments

Total Assets

CN¥1.91 Billion
≈ $279.34 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2014)

This chart shows how Shanxi C&Y Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. Check Shanxi C&Y Pharmaceutical Group Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Shanxi C&Y Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Shanxi C&Y Pharmaceutical Group Co Ltd market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥5.00 Million 0.26%
Total Liquid Assets CN¥5.00 Million 0.26%

Asset Resilience Insights

  • Limited Liquidity: Shanxi C&Y Pharmaceutical Group Co Ltd maintains only 0.26% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shanxi C&Y Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shanxi C&Y Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 48.48%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 11.69%
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
Drug Manufacturers - Specialty & Generic 4.31%
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
Drug Manufacturers - Specialty & Generic 15.57%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
Drug Manufacturers - Specialty & Generic 18.70%

Annual Asset Resilience Ratio for Shanxi C&Y Pharmaceutical Group Co Ltd (2013–2014)

The table below shows the annual Asset Resilience Ratio data for Shanxi C&Y Pharmaceutical Group Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2014-12-31 1.84% CN¥21.76 Million
≈ $3.18 Million
CN¥1.18 Billion
≈ $172.87 Million
+1.81pp
2013-12-31 0.04% CN¥388.94K
≈ $56.91K
CN¥1.09 Billion
≈ $159.56 Million
--
pp = percentage points

About Shanxi C&Y Pharmaceutical Group Co Ltd

SHE:300254 China Drug Manufacturers - Specialty & Generic
Market Cap
$293.39 Million
CN¥2.00 Billion CNY
Market Cap Rank
#14810 Global
#4350 in China
Share Price
CN¥7.83
Change (1 day)
+3.85%
52-Week Range
CN¥7.27 - CN¥14.68
All Time High
CN¥31.09
About

ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, comme… Read more